Replies to post #13238 on Inovio Pharmaceuticals Inc (INO)

[Ubertino]

hepatitis b virus

INO-1800 SynCon® immunotherapy for hepatitis B virus


Preclinical

Hepatitis B virus
Milestone

Initiated phase I trial 2Q 2015

Description
INO-1800 is a multi-antigen SynCon® DNA immunotherapy targeting hepatitis B virus clades A & C surface antigens & HBV core antigens.

Development Status
In 2013, Inovio entered into an exclusive worldwide collaboration with Roche to develop and commercialize Inovio’s hepatitis B multi-antigen DNA immunotherapy. The initiation of a phase I trial began in 2Q 2015 to test the safety, tolerability, and immunogenicity of INO-1800 alone or in combination with INO-9112, Inovio’s IL-12-based immune activator.

http://www.inovio.com/products/infectious-disease-vaccines/hepatitis/hbv/

Roche video: